Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galectin Q2 net loss widens
The company’s operating loss for the second quarter of 2011 was $2.99m, compared to $1.35m for the same period in 2010. For the six months ended 30 June
The company’s operating loss for the second quarter of 2011 was $2.99m, compared to $1.35m for the same period in 2010. For the six months ended 30 June
Qcell is an advanced formulation of Coenzyme Q10 (CoQ10) supplement formerly marketed under the brand name Q-Best. Qcell has demonstrated increased absorption rates by up to 10-fold compared
The company has posted a net income of $673,000 for the second quarter of 2011, compared to $1.35m for the same period in 2010. The company’s operating income
Volini Duo, which is developed using advanced Matrix technology, is a bi-layered Acetaminophen tablet, specially formulated to give dual pain relief. Matrix technology allows the regulated release of
The trial is being organized in Australia, Canada, France, the UK and the US under a special protocol assessment (SPA) granted by the US Food and Drug Administration
As per the terms of the agreement, CHDI will fund Isis to identify and conduct IND-enabling studies on an antisense drug targeting the huntingtin gene. Additionally, Isis is
Transgenomic’s net loss was $6m, compared to $1.15m for the same period in the prior year. The company’s loss from operations was $1.62m for the second quarter ended
Mylan‘s Alfuzosin Hydrochloride Extended-release Tablets, 10mg are generic equivalent to Uroxatral, indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. Uroxatral belongs to a group
Avanir alleged that Par’s and Actavis’ proposed generic products infringe certain patents held by the company. The law suit was filed based on the response to abbreviated new
ChromaDex’s net loss was $1.84m, compared to $303,529 for the same period in the prior year. The company’s operating loss was $1.83m for the second quarter ended July